title: Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient.
abstract: Bevacizumab, which is a humanized monoclonal antibody against vascular endothelial growth factor, is used to treat metastatic cancers of the colon. Adverse effects common with bevacizumab treatment are hypertension, arterial-venous thrombosis, bleeding, gastrointestinal perforation, and proteinuria. To date, there have been no reports of refractory seizure following treatment with bevacizumab. We describe a patient who presented with refractory generalized tonic-clonic seizures after receiving last dose of bevacizumab for treatment of metastatic colorectal cancer with FOLFIRI and bevacizumab regimen.
authors: Department of Medical Oncology, Erciyes University Medical School, 38039 Kayseri, Turkey. veliberk@gmail.com
authors: Veli
authors: V
authors: Berk
authors: Sevda
authors: S
authors: Ismailogullari
authors: Halil
authors: H
authors: Donmez
authors: Halit
authors: H
authors: Karaca
authors: Mevlude
authors: M
authors: Inanc
authors: Metin
authors: M
authors: Ozkan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000927:Anticonvulsants / Q000627:therapeutic use; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D012640:Seizures / Q000188:drug therapy / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000927:Anticonvulsants; D000068258:Bevacizumab